Literature DB >> 8798518

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach.

R P Pauly1, F Rosche, M Wermann, C H McIntosh, R A Pederson, H U Demuth.   

Abstract

The incretins glucose-dependent insulinotropic polypeptide (GIP1-42) and glucagon-like peptide-1-(7-36)-amide (GLP-17-36), hormones that potentiate glucose-induced insulin secretion from the endocrine pancreas, are substrates of the circulating exopeptidase dipeptidyl peptidase IV and are rendered biologically inactive upon cleavage of their N-terminal dipeptides. This study was designed to determine if matrix-assisted laser desorption/ionization-time of flight mass spectrometry is a useful analytical tool to study the hydrolysis of these hormones by dipeptidyl peptidase IV, including kinetic analysis. Spectra indicated that serum-incubated peptides were cleaved by this enzyme with only minor secondary degradation due to other serum protease activity. Quantification of the mass spectrometric signals allowed kinetic constants for both porcine kidney- and human serum dipeptidyl peptidase IV-catalyzed incretin hydrolysis to be calculated. The binding constants (Km) of these incretins to purified porcine kidney-derived enzyme were 1.8 +/- 0.3 and 3.8 +/- 0.3 microM, whereas the binding constants observed in human serum were 39 +/- 29 and 13 +/- 9 microM for glucose-dependent-insulinotropic polypeptide and glucagon-like peptide-1-(7-36)-amide respectively. The large range of Km values found in human serum suggests a heterogeneous pool of enzyme. The close correlation between the reported kinetic constants and those previously described validates this novel approach to kinetic analysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798518     DOI: 10.1074/jbc.271.38.23222

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Gut hormones: the future of obesity treatment?

Authors:  Anne K McGavigan; Kevin G Murphy
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 2.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

3.  Therapeutic vaccine against DPP4 improves glucose metabolism in mice.

Authors:  Zhengda Pang; Hironori Nakagami; Mariana K Osako; Hiroshi Koriyama; Futoshi Nakagami; Hideki Tomioka; Munehisa Shimamura; Hitomi Kurinami; Yoichi Takami; Ryuichi Morishita; Hiromi Rakugi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

4.  Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.

Authors:  V A Gault; F P M O'Harte; P Harriott; M H Mooney; B D Green; P R Flatt
Journal:  Diabetologia       Date:  2003-02-12       Impact factor: 10.122

5.  Dipeptidyl-peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans.

Authors:  A Beauvais; M Monod; J Wyniger; J P Debeaupuis; E Grouzmann; N Brakch; J Svab; A G Hovanessian; J P Latgé
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.

Authors:  Tsuyoshi Yanagimachi; Yukihiro Fujita; Yasutaka Takeda; Jun Honjo; Kuralay K Atageldiyeva; Yumi Takiyama; Atsuko Abiko; Yuichi Makino; Timothy J Kieffer; Masakazu Haneda
Journal:  Diabetologia       Date:  2015-12-22       Impact factor: 10.122

Review 7.  Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.

Authors:  Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-08       Impact factor: 3.575

8.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; Mark H Mooney; Finbarr P M O'harte
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

9.  Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.

Authors:  Mala Dharmalingam; Usha Sriram; Manash P Baruah
Journal:  Indian J Endocrinol Metab       Date:  2011-01

10.  High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes.

Authors:  Tiziana Sinagra; Sara Merlo; Simona F Spampinato; Rocco De Pasquale; Maria Angela Sortino
Journal:  Front Pharmacol       Date:  2015-06-16       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.